Development of Capsule containing Immediate Release Tablet and Extended Release Floating Tablet for Monitoring Release of Atenolol
Atenolol is beta blocker absorbed through GIT use for heart diseases. Single tablets, floating tablets and sustained released formulations studied are insufficient to produce effective dose to enhance bioavailability and effectiveness. Our study is focused on development of capsule dosage form conta...
Gespeichert in:
Veröffentlicht in: | Research journal of pharmacy and technology 2021-04, Vol.14 (4), p.2216-2220 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2220 |
---|---|
container_issue | 4 |
container_start_page | 2216 |
container_title | Research journal of pharmacy and technology |
container_volume | 14 |
creator | Kolhe, Mahesh Hari Gilhotra, Ritu Mehra Asane, Govind Sarangdhar |
description | Atenolol is beta blocker absorbed through GIT use for heart diseases. Single tablets, floating tablets and sustained released formulations studied are insufficient to produce effective dose to enhance bioavailability and effectiveness. Our study is focused on development of capsule dosage form containing immediate release (IR) and floating extended release (ER) tablets for monitoring release of atenolol in single dosage form. Two different tablets for IR and ER were prepared in three different combinations (Batch). Pre-formulation and post formulation parameters found to be within acceptable limits of formulation. Release behavior of individual tablets and capsule containing two tablets were studied. Among the batches, capsules containing smaller amount of atenolol in IR and large amount of Atenolol in ER (batch II) showed impressive drug release pattern. This formulation was stable even after a month and achieved optimum release behavior of immediate release and sustained release. This study could be used for effective treatment for different heart complications and reduce toxicity due to high plasma concentration in increased dose frequency. |
doi_str_mv | 10.52711/0974-360X.2021.00393 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2533806935</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2533806935</sourcerecordid><originalsourceid>FETCH-LOGICAL-c196t-2cb0f8ac3b78e8980bfadcd1e1c6521f274712087af57fca6fe19c21f1b2ec3a3</originalsourceid><addsrcrecordid>eNo9kF9LwzAUxYMoOOY-ghDwuTN_1jZ9HHPTwUSQCb6FNL2RjrSpSSb66ie33ebuy72ce8698EPolpJpynJK70mRzxKekfcpI4xOCeEFv0Cjs3x5nqm4RpMQdqSvTKRsJkbo9wG-wLqugTZiZ_BCdWFvAWvXRlW3dfuB100DVa0i4FewoALgrSotRKzaCi-_I7QVVOfdyjoVh9jJZJzHz66to_OD-m_rX837pLPO3qAro2yAyamP0dtquV08JZuXx_Vivkk0LbKYMF0SI5TmZS5AFIKURlW6okB1ljJqWD7LKSMiVybNjVaZAVrofkFLBporPkZ3x7udd597CFHu3N63_UvJUs4FyQqe9q706NLeheDByM7XjfI_khJ5IC4HnHJAKwfi8kCc_wGACXXv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2533806935</pqid></control><display><type>article</type><title>Development of Capsule containing Immediate Release Tablet and Extended Release Floating Tablet for Monitoring Release of Atenolol</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Kolhe, Mahesh Hari ; Gilhotra, Ritu Mehra ; Asane, Govind Sarangdhar</creator><creatorcontrib>Kolhe, Mahesh Hari ; Gilhotra, Ritu Mehra ; Asane, Govind Sarangdhar</creatorcontrib><description>Atenolol is beta blocker absorbed through GIT use for heart diseases. Single tablets, floating tablets and sustained released formulations studied are insufficient to produce effective dose to enhance bioavailability and effectiveness. Our study is focused on development of capsule dosage form containing immediate release (IR) and floating extended release (ER) tablets for monitoring release of atenolol in single dosage form. Two different tablets for IR and ER were prepared in three different combinations (Batch). Pre-formulation and post formulation parameters found to be within acceptable limits of formulation. Release behavior of individual tablets and capsule containing two tablets were studied. Among the batches, capsules containing smaller amount of atenolol in IR and large amount of Atenolol in ER (batch II) showed impressive drug release pattern. This formulation was stable even after a month and achieved optimum release behavior of immediate release and sustained release. This study could be used for effective treatment for different heart complications and reduce toxicity due to high plasma concentration in increased dose frequency.</description><identifier>ISSN: 0974-3618</identifier><identifier>EISSN: 0974-360X</identifier><identifier>EISSN: 0974-306X</identifier><identifier>DOI: 10.52711/0974-360X.2021.00393</identifier><language>eng</language><publisher>Raipur: A&V Publications</publisher><subject>Bioavailability ; Drug dosages ; Heart rate</subject><ispartof>Research journal of pharmacy and technology, 2021-04, Vol.14 (4), p.2216-2220</ispartof><rights>Copyright A&V Publications Apr 2021</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c196t-2cb0f8ac3b78e8980bfadcd1e1c6521f274712087af57fca6fe19c21f1b2ec3a3</citedby><cites>FETCH-LOGICAL-c196t-2cb0f8ac3b78e8980bfadcd1e1c6521f274712087af57fca6fe19c21f1b2ec3a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27931,27932</link.rule.ids></links><search><creatorcontrib>Kolhe, Mahesh Hari</creatorcontrib><creatorcontrib>Gilhotra, Ritu Mehra</creatorcontrib><creatorcontrib>Asane, Govind Sarangdhar</creatorcontrib><title>Development of Capsule containing Immediate Release Tablet and Extended Release Floating Tablet for Monitoring Release of Atenolol</title><title>Research journal of pharmacy and technology</title><description>Atenolol is beta blocker absorbed through GIT use for heart diseases. Single tablets, floating tablets and sustained released formulations studied are insufficient to produce effective dose to enhance bioavailability and effectiveness. Our study is focused on development of capsule dosage form containing immediate release (IR) and floating extended release (ER) tablets for monitoring release of atenolol in single dosage form. Two different tablets for IR and ER were prepared in three different combinations (Batch). Pre-formulation and post formulation parameters found to be within acceptable limits of formulation. Release behavior of individual tablets and capsule containing two tablets were studied. Among the batches, capsules containing smaller amount of atenolol in IR and large amount of Atenolol in ER (batch II) showed impressive drug release pattern. This formulation was stable even after a month and achieved optimum release behavior of immediate release and sustained release. This study could be used for effective treatment for different heart complications and reduce toxicity due to high plasma concentration in increased dose frequency.</description><subject>Bioavailability</subject><subject>Drug dosages</subject><subject>Heart rate</subject><issn>0974-3618</issn><issn>0974-360X</issn><issn>0974-306X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNo9kF9LwzAUxYMoOOY-ghDwuTN_1jZ9HHPTwUSQCb6FNL2RjrSpSSb66ie33ebuy72ce8698EPolpJpynJK70mRzxKekfcpI4xOCeEFv0Cjs3x5nqm4RpMQdqSvTKRsJkbo9wG-wLqugTZiZ_BCdWFvAWvXRlW3dfuB100DVa0i4FewoALgrSotRKzaCi-_I7QVVOfdyjoVh9jJZJzHz66to_OD-m_rX837pLPO3qAro2yAyamP0dtquV08JZuXx_Vivkk0LbKYMF0SI5TmZS5AFIKURlW6okB1ljJqWD7LKSMiVybNjVaZAVrofkFLBporPkZ3x7udd597CFHu3N63_UvJUs4FyQqe9q706NLeheDByM7XjfI_khJ5IC4HnHJAKwfi8kCc_wGACXXv</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Kolhe, Mahesh Hari</creator><creator>Gilhotra, Ritu Mehra</creator><creator>Asane, Govind Sarangdhar</creator><general>A&V Publications</general><scope>AAYXX</scope><scope>CITATION</scope><scope>04Q</scope><scope>04S</scope><scope>04W</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20210401</creationdate><title>Development of Capsule containing Immediate Release Tablet and Extended Release Floating Tablet for Monitoring Release of Atenolol</title><author>Kolhe, Mahesh Hari ; Gilhotra, Ritu Mehra ; Asane, Govind Sarangdhar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c196t-2cb0f8ac3b78e8980bfadcd1e1c6521f274712087af57fca6fe19c21f1b2ec3a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Bioavailability</topic><topic>Drug dosages</topic><topic>Heart rate</topic><toplevel>online_resources</toplevel><creatorcontrib>Kolhe, Mahesh Hari</creatorcontrib><creatorcontrib>Gilhotra, Ritu Mehra</creatorcontrib><creatorcontrib>Asane, Govind Sarangdhar</creatorcontrib><collection>CrossRef</collection><collection>India Database</collection><collection>India Database: Business</collection><collection>India Database: Science & Technology</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Research journal of pharmacy and technology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kolhe, Mahesh Hari</au><au>Gilhotra, Ritu Mehra</au><au>Asane, Govind Sarangdhar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of Capsule containing Immediate Release Tablet and Extended Release Floating Tablet for Monitoring Release of Atenolol</atitle><jtitle>Research journal of pharmacy and technology</jtitle><date>2021-04-01</date><risdate>2021</risdate><volume>14</volume><issue>4</issue><spage>2216</spage><epage>2220</epage><pages>2216-2220</pages><issn>0974-3618</issn><eissn>0974-360X</eissn><eissn>0974-306X</eissn><abstract>Atenolol is beta blocker absorbed through GIT use for heart diseases. Single tablets, floating tablets and sustained released formulations studied are insufficient to produce effective dose to enhance bioavailability and effectiveness. Our study is focused on development of capsule dosage form containing immediate release (IR) and floating extended release (ER) tablets for monitoring release of atenolol in single dosage form. Two different tablets for IR and ER were prepared in three different combinations (Batch). Pre-formulation and post formulation parameters found to be within acceptable limits of formulation. Release behavior of individual tablets and capsule containing two tablets were studied. Among the batches, capsules containing smaller amount of atenolol in IR and large amount of Atenolol in ER (batch II) showed impressive drug release pattern. This formulation was stable even after a month and achieved optimum release behavior of immediate release and sustained release. This study could be used for effective treatment for different heart complications and reduce toxicity due to high plasma concentration in increased dose frequency.</abstract><cop>Raipur</cop><pub>A&V Publications</pub><doi>10.52711/0974-360X.2021.00393</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0974-3618 |
ispartof | Research journal of pharmacy and technology, 2021-04, Vol.14 (4), p.2216-2220 |
issn | 0974-3618 0974-360X 0974-306X |
language | eng |
recordid | cdi_proquest_journals_2533806935 |
source | EZB-FREE-00999 freely available EZB journals |
subjects | Bioavailability Drug dosages Heart rate |
title | Development of Capsule containing Immediate Release Tablet and Extended Release Floating Tablet for Monitoring Release of Atenolol |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T09%3A49%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20Capsule%20containing%20Immediate%20Release%20Tablet%20and%20Extended%20Release%20Floating%20Tablet%20for%20Monitoring%20Release%20of%20Atenolol&rft.jtitle=Research%20journal%20of%20pharmacy%20and%20technology&rft.au=Kolhe,%20Mahesh%20Hari&rft.date=2021-04-01&rft.volume=14&rft.issue=4&rft.spage=2216&rft.epage=2220&rft.pages=2216-2220&rft.issn=0974-3618&rft.eissn=0974-360X&rft_id=info:doi/10.52711/0974-360X.2021.00393&rft_dat=%3Cproquest_cross%3E2533806935%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2533806935&rft_id=info:pmid/&rfr_iscdi=true |